Skip to main content
. 2023 Aug 7;208(9):915–916. doi: 10.1164/rccm.202307-1200VP

Figure 1.


Figure 1.

Baseline and change in sweat chloride (A) and FEV1% predicted (B) in people with cystic fibrosis who initiated treatment with generic elexacaftor/tezacaftor/ivacaftor on a standard, modulator-sparing, or a combination of dosing strategies. Markers indicate mean values and vertical bars 95% confidence intervals.